No title
Background Circadian rhythms regulate immune cell trafficking and function, and emerging clinical data suggest that the timing of immune checkpoint inhibitor (ICI) administration may influence efficacy. In advanced disease, later-day administration has been associated with inferior outcomes. Whether this applies to neoadjuvant ICI in resectable stage III–IV melanoma is unknown. Methods This retros
